Inflarx Assessing Feasibility Of Broadened Strategy For Anca‑Associated Vasculitis In Europe Following EMA Recommendation On Tavneos

InflaRx NV NASDAQ:IFRX:

• INFLARX ASSESSING FEASIBILITY OF BROADENED STRATEGY FOR ANCA‑ASSOCIATED VASCULITIS IN EUROPE FOLLOWING EMA RECOMMENDATION ON TAVNEOS

• INFLARX NV - TO ENGAGE WITH EMA ON VILOBELIMAB AND IZICOPAN FOR AAV APPROVAL